The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, Dose-Ra

Interleukin-6 inhibitors in the treatment of rheumatoid arthritis

(2016) Arthur Kavanaugh   Therapeutics and Clinical Risk Management

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

(2014) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy

(2014) Toshio Tanaka et al.   SEMINARS IN IMMUNOLOGY

Interleukin 6 and Rheumatoid Arthritis

(2014) Yuji Yoshida et al.   Biomed Research International

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial

(2013) Tom W J Huizinga et al.   ANNALS OF THE RHEUMATIC DISEASES

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate

(2012) P Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

(2012) Stefan Rose-John   International Journal of Biological Sciences

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

(2011) David T. Felson et al.   ARTHRITIS AND RHEUMATISM

Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

(2011) Boulos Haraoui et al.   BMC MUSCULOSKELETAL DISORDERS

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative

(2010) Daniel Aletaha et al.   ARTHRITIS AND RHEUMATISM

Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor

(2009) Jean-Michel Dayer et al.   RHEUMATOLOGY

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study

(2008) N Nishimoto et al.   ANNALS OF THE RHEUMATIC DISEASES